Advocates for patients with Alzheimer’s disease are welcoming the recommendation to fund lecanemab, viewing it as a long-overdue advancement in neurodegenerative care. For decades, treatment options for Alzheimer’s have been limited to managing symptoms, offering little hope for slowing the actual progression of the disease. By clearing amyloid plaques, lecanemab offers a tangible way to preserve cognitive function for a longer period, potentially allowing patients to maintain their independence and quality of life for months or even years longer than previously possible.
Proponents argue that the cost of inaction is far higher than the price of the drug. When patients lose their cognitive abilities prematurely, the burden on the healthcare system and caregivers increases exponentially. Providing access to this treatment is seen as a proactive investment in patient health that could delay the need for long-term institutional care. For families, the ability to have more time with a loved one who is still able to communicate and engage is considered an invaluable benefit that justifies the public expenditure.
Furthermore, supporters emphasize that the rigorous criteria set by the agency will ensure the drug is used safely and effectively. By focusing on patients in the early stages of the disease, the health system can maximize the clinical impact of the treatment. This targeted approach provides a clear framework for clinicians to identify candidates who are most likely to see meaningful results, ensuring that public resources are directed toward those who can benefit the most from this new therapeutic option.